CD79A and COVID-19: We also observed lower levels of autoantibodies against NMDA receptors (IgA), glutamic acid decarboxylase 65 (IgG), amyloid β peptide (IgG), tau protein (IgG), enteric nerve (IgG), and S100-B (IgG) in COVID-19 patients compared with healthy controls (Table 1).